At 2.2% CAGR, the Middle East & Africa Acute Pancreatitis Market is projected to be worth US$ 156.24 million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Middle East & Africa acute pancreatitis market was valued at US$ 131.64 million in 2022 and is expected to reach US$ 156.24 million by 2030, registering a CAGR of 2.2% from 2022 to 2030. Rise in pancreatic cancer cases due to acute pancreatitis and rising incidence of diabetes following acute pancreatitis are the critical factors attributed to the Middle East & Africa acute pancreatitis market expansion.             

Acute pancreatitis, which causes the release of digestive enzymes into the pancreatic interstitial space instead of the pancreatic duct lumen, could be an early indicator of pancreatic cancer due to tumor obstruction of the pancreatic duct. Acute pancreatitis is a painful condition, so patients seek medical care sooner, which could lead to an early cancer diagnosis. Globally, there were 2,814,972.3 instances of acute pancreatitis in 2019, among which 1,541,017.1 cases in males and 1,273,955.2 cases in women were identified. Acute pancreatitis caused 3,641,105.7 disability-adjusted life-years (DALYs) and 115,053.2 deaths in 2019. Therefore, rising cases of pancreatic cancer due to acute pancreatitis boosts the growth of the acute pancreatitis market.

On the contrary, side effects of pancreatitis and pancreatic cancer treatments hampers on the growth of Middle East & Africa acute pancreatitis market. 

Based on offerings, the Middle East & Africa acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held 56.0% share of Middle East & Africa acute pancreatitis market in 2022, amassing US$ 73.66 million. It is projected to garner US$ 87.05 million by 2030 to expand at 2.1% CAGR during 2022–2030.

Based on causes, the Middle East & Africa acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held 49.5% share of Middle East & Africa acute pancreatitis market in 2022, amassing US$ 65.12 million. It is projected to garner US$ 78.93 million by 2030 to expand at 2.4% CAGR during 2022–2030.

Based on end user, the Middle East & Africa acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held 74.0% share of Middle East & Africa acute pancreatitis market in 2022, amassing US$ 97.44 million. It is projected to garner US$ 114.91 million by 2030 to expand at 2.1% CAGR during 2022–2030.

Based on country, the Middle East & Africa acute pancreatitis market has been categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 34.0% share of Middle East & Africa acute pancreatitis market in 2022. It was assessed at US$ 44.69 million in 2022 and is likely to hit US$ 51.80 million by 2030, exhibiting a CAGR of 1.9% during 2022–2030.            

Key players operating in the Middle East & Africa acute pancreatitis market are Abbott Laboratories, Baxter International Inc, Boston Scientific Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare, among others.

• In Oct 2021, Samsung Medison, a global medical equipment company and an affiliate of Samsung Electronics, introduced the V8, a new high-end ultrasound system that provides enhanced image quality, usability and convenience for all medical professionals.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com